A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Sponsor
LaNova Medicines Zhejiang Co., Ltd.
Study ID
NCT05934331
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Malignant Neoplasms of Digestive Organs

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • LM-302 — DRUG
    Q2W/Q3W，Administered intravenously
  • Toripalimab — DRUG
    Q2W/Q3W,Administered intravenously
  • Capecitabine — DRUG
    BID,Oral Administration
  • Tegafur, Gimeracil and Oteracil Potassium Capsules — DRUG
    BID,Oral Administration
  • Nivolumab — DRUG
    Q4W,Administered intravenously
  • Apatinib — DRUG
    QD,Oral Administration
  • Gemcitabine — DRUG
    Q4W,Administered intravenously

Study Details

This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.

Key Dates

Start date
Jul 27, 2023
Status verified
Sep 2025
Primary completion
Jul 1, 2026
Completion
Jul 1, 2028

Study Design

Enrollment
276 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: LM-302 in combination with Toripalimab
  • Experimental: LM-302 in combination with other therapies

Primary Outcome Measure

PFS [ Time Frame: 112 weeks ]

Central Contacts